Bruker (NASDAQ:BRKR) Rating Increased to Neutral at The Goldman Sachs Group

Bruker (NASDAQ:BRKR) was upgraded by stock analysts at The Goldman Sachs Group from a “sell” rating to a “neutral” rating in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The firm presently has a $60.00 price objective on the medical research company’s stock. The Goldman Sachs Group’s target price points to a potential upside of 0.84% from the company’s previous close.

A number of other equities analysts also recently weighed in on BRKR. Wells Fargo & Company cut their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. TD Cowen cut their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Wolfe Research downgraded shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Barclays dropped their price objective on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Finally, Citigroup dropped their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Bruker currently has an average rating of “Moderate Buy” and an average price target of $79.36.

Bruker Trading Up 3.4 %

Shares of Bruker stock opened at $59.50 on Thursday. Bruker has a 52-week low of $48.07 and a 52-week high of $94.86. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The company’s 50-day simple moving average is $60.08 and its 200-day simple moving average is $63.64. The firm has a market cap of $9.02 billion, a price-to-earnings ratio of 28.61, a price-to-earnings-growth ratio of 3.86 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. During the same quarter in the previous year, the company posted $0.74 earnings per share. The company’s quarterly revenue was up 16.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Bruker will post 2.4 earnings per share for the current year.

Insider Transactions at Bruker

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of Bruker stock in a transaction dated Monday, November 18th. The shares were bought at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the transaction, the chief executive officer now owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This represents a 0.26 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 28.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BRKR. Sanctuary Advisors LLC lifted its position in Bruker by 95.8% in the 3rd quarter. Sanctuary Advisors LLC now owns 9,089 shares of the medical research company’s stock valued at $628,000 after purchasing an additional 4,447 shares during the last quarter. Coldstream Capital Management Inc. lifted its position in Bruker by 7.3% in the 3rd quarter. Coldstream Capital Management Inc. now owns 4,553 shares of the medical research company’s stock valued at $312,000 after purchasing an additional 308 shares during the last quarter. Geode Capital Management LLC lifted its position in Bruker by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company’s stock valued at $137,702,000 after purchasing an additional 193,580 shares during the last quarter. Barclays PLC lifted its position in Bruker by 36.5% in the 3rd quarter. Barclays PLC now owns 55,685 shares of the medical research company’s stock valued at $3,847,000 after purchasing an additional 14,888 shares during the last quarter. Finally, MML Investors Services LLC lifted its position in Bruker by 9.2% in the 3rd quarter. MML Investors Services LLC now owns 31,820 shares of the medical research company’s stock valued at $2,198,000 after purchasing an additional 2,693 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.